Join Us “Inside the Lab at Boston”
The work of type 1 diabetes (T1D) researchers is so compelling and full of hope. But it also is a…
Breakthrough T1D Funded Researcher Receives Prestigious Jacobus Prize
Mark Atkinson, Ph.D., a longtime Breakthrough T1D-funded researcher, is the recipient of 2019 Jacobus Prize for his research into the…
ViaCyte Does it Again: Insulin Production in People with T1D
ViaCyte, a beta cell replacement company long supported by Breakthrough T1D, has shown—for the first time ever—that its PEC-Direct therapy…
Trick or Treat: Have a scare-free and fun Halloween
To say that Halloween is ‘fun’ is an understatement! So many kids and adults look forward to this one evening…
EASD Brings World-Renowned Minds to Barcelona
For 55 years, leading researchers from around the world have gathered for the annual meeting of the European Association for…
Breakthrough T1D and Beyond Type 1 Launch Alliance
Today we announced an exciting new alliance with Beyond Type 1, aimed at getting more information, more resources, and more…
Breakthrough T1D Clinical Trial Results Announced at the 55th EASD Meeting
A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body. If blood glucose…
The Best of the Best: Researchers Unite at the 55th EASD Annual Meeting
For 55 years, leading researchers from around the world have gathered for the annual meeting of the European Association for…
FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia
On Tuesday, the type 1 diabetes (T1D) community got a helping hand in their ability to avoid severe hypoglycemia when…
Breakthrough T1D Launches First Center of Excellence, Aiming to Accelerate Type 1 Diabetes Research
Breakthrough T1D today launched its first Center of Excellence, a new research and funding model aimed at accelerating leading type…
